about
Buttonhole cannulation and clinical outcomes in a home hemodialysis cohort and systematic reviewThe Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry studyRole of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation.Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial.Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) studyEnd-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases.Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients.Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases.Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients.Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study.The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: an interventional cohort study.Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report.The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study.The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial.A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients--the HEALTHY-CATH trial.A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.The association between body mass index and mortality in incident dialysis patients.Cardiorespiratory fitness is independently associated with 25-hydroxyvitamin D in chronic kidney disease.Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation.Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia.Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients.N-terminal pro-B-type natriuretic peptide variability in stable dialysis patientsUtility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ TrialThe role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patientsLeft Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease.The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modificationsLeft ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney diseaseMycophenolic acid pharmacokinetics and related outcomes early after renal transplantSocio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients.An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia and New Zealand Dialysis and Transplantation Registry).
P50
Q26861548-16F493AB-39E8-41C4-9B93-E6A6AFE260DDQ30249801-049E08B8-4AEB-40FD-953B-89A2985E7DB3Q30251447-2F9F25F8-16B5-47E0-8988-B1C7910AF138Q30560814-85C8FF1C-0080-471D-8AE2-5EAAF243437CQ32186756-7D8A2E15-2D2D-4EED-9CB8-5685B3C89F87Q33356816-93344DBF-CDE5-4895-896E-945A6D165C0CQ33367420-3D5D2803-99C5-4BE5-A043-431575BE6A15Q33401679-CFB0D45F-C6E0-4789-B5B0-07C53E7AA512Q33404656-15880A7F-B08E-4A36-8049-72C0A68394D2Q33412869-A6BF3FC2-6FE6-45EC-97FE-A738060E4F1CQ33424946-18DD1F75-D612-4F95-B4C5-945884CCB14CQ33432770-58C2E133-8E4B-4626-806A-FB38939F90D4Q33461866-D67DB3CD-810C-4ABA-8B31-0CA4EB020687Q33486767-DA8631DD-ED96-4623-B05A-21D0ADC5BF19Q33487493-18AEB183-EA8B-476A-A22F-8F5190863175Q33494980-17994E9A-6600-41CC-A71F-C45CA7F17FFBQ33509887-544C5A73-40B8-4F08-AA31-0B262A6E659EQ33517923-DB868CF9-0F23-4CC1-9F30-370C2F206F9DQ34036386-7B88DC25-F302-41D7-8C57-50DCD264F38BQ34098083-16F4E464-8191-427F-B3A7-00FE0AED5B5AQ34306126-D8089D90-6989-4F18-A306-80C21471AAACQ34452637-36394220-535C-4E71-9E74-BEAEC5A85AE6Q34465850-B91FC200-4E1E-4C69-91DE-837724994360Q34516576-C657BD8B-F0A5-4700-A328-68296CA59944Q34712804-18530BEF-BEE3-4EF7-BD16-7E889B35275EQ34857646-95783297-AD9A-40B5-8E4C-3364D2E2CA02Q35068106-46373088-892E-48B7-A745-72BEB7B86A66Q35075913-6E140BB2-02B8-4126-9B00-27B5194C4813Q35106066-1A1CAC3E-D69B-45C3-BC5B-D88139EED0D4Q35141392-9319A2E6-8D40-4DAE-8513-EBC63930605BQ35278624-E5159B9E-863D-4AF0-8909-E6E1D6401E1FQ35524711-A611D568-E853-424A-B0B7-DC045C516EEFQ35524820-A92F352F-D07A-4C1A-AC62-4E8066AD1BCEQ35573890-011DE470-EE67-4195-905C-E9C43F891064Q35610795-B049184D-BC6A-4260-9095-F81A3D3C4E29Q35676161-DBB46A8D-489F-4EA3-8B5D-EADD7CDA3D2DQ35695693-BD855CA2-A9BF-4F21-A4B3-24B5CF30A8DDQ35826828-1A7C3268-7D0D-4887-A0A5-F387CD61937BQ35904430-D11D5806-66E1-4594-ADE5-474C4894D65EQ35922687-79820D5A-84F0-46F9-A83E-AB4D49C774B3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmel M Hawley
@es
Carmel M. Hawley
@en
Carmel M. Hawley
@nl
Carmel M. Hawley
@sl
type
label
Carmel M Hawley
@es
Carmel M. Hawley
@en
Carmel M. Hawley
@nl
Carmel M. Hawley
@sl
altLabel
C. Hawley
@en
C.M. Hawley
@en
Carmel Hawley
@en
Carmel Mary Hawley
@en
prefLabel
Carmel M Hawley
@es
Carmel M. Hawley
@en
Carmel M. Hawley
@nl
Carmel M. Hawley
@sl
P1053
C-4905-2011
P106
P1153
35444599100
P21
P31
P3829
P496
0000-0002-1392-5649
P569
2000-01-01T00:00:00Z